Review of the 2019 European Society of Cardiology Guidelines for the management of patients with supraventricular tachycardia: what is new and what has changed?. Modernized classification of cardiac anti-arrhythmic drugs. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.
Effectiveness of the Valsalva manoeuvre for reversion of supraventricular tachycardia. Modified Valsalva maneuver for treatment of supraventricular tachycardias: a meta-analysis. Potential for misdiagnosis as panic disorder. Unrecognized paroxysmal supraventricular tachycardia. Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Tachycardiomyopathy: mechanisms and clinical implications. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). 2019 ESC guidelines for the management of patients with supraventricular tachycardia. Evaluation and initial treatment of supraventricular tachycardia. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Pappone C, Vicedomini G, Manguso F, et al.
Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. The ESC Textbook of Cardiovascular Medicine. Atrioventricular nodal reentrant tachycardia. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Paroxysmal supraventricular tachycardia in the general population. Orejarena LA, Vidaillet H, DeStefano F, et al. Common types of supraventricular tachycardia: diagnosis and management. Diagnosis and management of common types of supraventricular tachycardia. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Catheter ablation has a high success rate and is recommended as the first-line method for long-term management of recurrent, symptomatic paroxysmal SVT, including Wolff-Parkinson-White syndrome. Clinicians should use a patient-centered approach when formulating a long-term management plan for atrioventricular nodal reentrant tachycardia. When evaluating patients for paroxysmal SVTs, clinicians should have a low threshold for referral to a cardiologist for electrophysiologic study and appropriate intervention such as ablation. Beta blockers and/or calcium channel blockers may be used acutely or for long-term suppressive therapy. In those who are hemodynamically stable, vagal maneuvers are first-line management, followed by stepwise medication management if ineffective. In patients who are hemodynamically unstable, synchronized cardioversion is first-line management. Acute management of paroxysmal SVT is similar across the various types and is best completed in the emergency department or hospital setting. Extended cardiac monitoring with a Holter monitor or event recorder may be needed to confirm the diagnosis. Diagnostic evaluation may be performed in the outpatient setting and includes a comprehensive history and physical examination, electrocardiography, and laboratory workup. Presenting symptoms may include altered consciousness, chest pressure or discomfort, dyspnea, fatigue, lightheadedness, or palpitations.
Paroxysmal SVT, a subset of supraventricular dysrhythmias, has three common types: atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, and atrial tachycardia. Supraventricular tachycardia (SVT) is an abnormal rapid cardiac rhythm that involves atrial or atrioventricular node tissue from the His bundle or above.
0 kommentar(er)
